GW Pharma aiming for FDA approval for CBD drug this year, again

British cannabis company GW Pharmaceuticals is hoping the U.S. Food and Drug Administration will sign off on its CBD-based epilepsy treatment, Epidiolex, as soon as this year. According to The Washington Post, GW is hoping to get the green light from the FDA to classify Epidiolex as a prescription drug, despite the fact it’s derived […] GW Pharma aiming for FDA approval for CBD drug this year, again is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs